Precisio Biotix Therapeutics

Ownership

Private

Therapeutic Areas

Infectious Diseases

Stage

Clinical

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Lysins (engineered precision enzymes)bacteriophages (phages)

Precisio Biotix Therapeutics General Information

Precisio Biotix is developing novel precision biological antibacterials with a focus on lung and skin infections. The company has a pipeline of lysin and phage products targeting antimicrobial-resistant infections.

Contact Information

Website

http://www.precisiobiotix.com/

Primary Industry

Biotech

Corporate Office

Dover, Delaware
United States

Drug Pipeline

No pipeline data available

For full access to Precisio Biotix Therapeutics's pipeline data

Book a demo

Key Partnerships

Mayo Clinic, CC Bio (acquired)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Precisio Biotix Therapeutics Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view Precisio Biotix Therapeutics's complete valuation and funding history, request access »